Comparison
Berberine vs Noopept
Side-by-side of Berberine and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Berberine | Noopept |
|---|---|---|
| Category | natural | nootropic |
| Also known as | berberine HCl, berberine hydrochloride | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 3 | 0.7 |
| Typical dose (mg) ↗ | 1500 | 20 |
| Dosing frequency | 3x daily with meals | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 2 | 0.5 |
| Peak (hr) | 3 | 1 |
| Molecular weight | 336.36 | 318.37 |
| Molecular formula | C20H18NO4+ | C17H22N2O4 |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Not scheduled in the US |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Not recommended |
| CAS | 2086-83-1 | 157115-85-0 |
| PubChem CID | 2353 | 183503 |
| Wikidata | Q411435 | Q4321022 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
- → If your priority is focus or working memory, pick Noopept.
- → If your priority is memory, pick Noopept.
Edge case: If you want to avoid controlled substance, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and Noopept?
Berberine and Noopept differ in category (natural vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or Noopept?
Berberine half-life is 3 hours; Noopept half-life is 0.7 hours.
Can you stack Berberine with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper